Clinical Trials Arena July 22, 2022
The Covid-19 pandemic put human challenge trials in the spotlight, drawing attention to this design’s possibilities in infectious disease studies.
In the early months of the pandemic, human challenge clinical trials drew amplified public interest on its potential to accelerate the hunt for Covid-19 vaccines. Fast forward two years later, while mainstream media buzz around this trial design has somewhat tempered, this does not seem to be the case in the clinical trials sector, at least according to one service provider.
“There’s been unprecedented demand for human challenge trials recently,” says Open Orphan chief scientific officer Andrew Catchpole. “We are fully booked for the next 12 months. We added 19 extra beds to our pre-existing...
Today's Sponsors
Today's Sponsor